NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of Stride, Inc. (NYSE: LRN)?Did you purchase your shares between October 22, 2024 and October 28, 2025, inclusive?Did you lose money in your inve ...

Core Points - A class action lawsuit has been filed against KBR, Inc. on behalf of investors who acquired shares between May 6, 2025, and June 19, 2025 [1][2] - The lawsuit alleges that KBR misled investors regarding a contract with the U.S. Department of Defense's Transportation Command, despite internal concerns about the contract [3] - Following the announcement of the contract termination on June 19, 2025, KBR's stock price dropped by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4] Company Overview - KBR, headquartered in Houston, is a global provider of science, technology, and engineering solutions for governmental and commercial clients [2] Legal Context - Investors who purchased KBR securities during the class period have until November 18, 2025, to seek appointment as lead plaintiff [2]

New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your MoonLake Immunotherapeutics (NASDAQ: MLTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:https://zlk.com/pslra-1/moonlake-lawsuit-submission-form?prid=177687&wire=5&utm_campaign=1or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.Cann ...

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting shareholders between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple malfunctions, injuries, and deaths related to these defects but failed to take adequate remedial actions [3]. - The complaint states that Baxter's public statements regarding the safety, efficacy, and sales prospects of the Novum LVP were materially false and misleading [3]. Group 2: Next Steps for Shareholders - Shareholders who experienced losses in Baxter International, Inc. stock during the specified timeframe are encouraged to seek information on their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the U.S. for seven consecutive years [5].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries plc is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Financial Performance - The lawsuit claims that James Hardie misled investors by stating that its North American fiber cement segment showed "inherent strength" and "underlying momentum," while in reality, sales were inflated due to inventory loading by channel partners, indicating fraudulent channel stuffing rather than genuine customer demand [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales for the quarter, attributed to destocking efforts by customers, which was first noted in April and May. This revelation led to a stock price drop of $9.79 per share, or over 34%, from $28.43 to $18.64 [6].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, under the case caption Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75 per share, nearly 90%, from $61.99 on September 26, 2025, to $6.24 on September 29, 2025 [6].

Core Insights - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, as announced by Bleichmar Fonti & Auld LLP [1] - The company's primary brands, Premier Protein and Dymatize, have reported strong household penetration and demand, but this growth may be misleading due to temporary trade inventory loading rather than sustainable consumer demand [2] Company Performance - BellRing's stock experienced significant declines following revelations about inventory levels and consumption rates. On May 5, 2025, the stock fell by $13.96, or over 18%, after the company disclosed that key retailers had reduced their inventory levels, impacting future growth [3] - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a further decline of $17.46, or nearly 33%, in stock price the following day [4] Legal and Financial Implications - Investors in BellRing may have legal options available and are encouraged to seek further information regarding potential class action lawsuits [5] - Bleichmar Fonti & Auld LLP has a strong track record in securities class actions, having recovered significant amounts for shareholders in previous cases [6]

Core Insights - Coty Inc. is under investigation for potential violations of federal securities laws, with a focus on its financial disclosures and inventory management practices [1][2]. Company Overview - Coty is a major player in the beauty industry, with a diverse portfolio that includes fragrances, color cosmetics, and skin and body care products. Prestige fragrances represent 60% of the company's revenue [2]. Financial Performance - The company reported disappointing financial results for Q4 and FY 2025, attributing the decline to issues in U.S. execution, retailer inventory buildup, and challenges from previous fiscal year innovations. The stock price fell over 21%, from $4.86 to $3.81 per share following the announcement [3].

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against CarMax, Inc. (NYSE: KMX) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in CarMax, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/carmax-inc-class-action-lawsuit. In ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, under the case caption MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [2]. - Investors have until January 12, 2026, to request to be appointed to lead the case [2]. Group 2: Allegations Against Stride - Stride, an education technology company, allegedly inflated enrollment numbers by retaining "ghost students" and ignored compliance requirements, leading to a poor customer experience [3]. - The company claimed to be experiencing growth and strong demand, which is contradicted by the allegations of inflated enrollment and higher withdrawal rates [3]. Group 3: Stock Price Impact - Following the fraud allegations reported on September 14, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share [4]. - On October 28, 2025, Stride admitted to issues resulting in 10,000-15,000 fewer enrollments, causing its stock to plummet by $83.48, or more than 54%, from $153.53 to $70.05 per share [5].